Why In-Person Clinics Deliver 2-5X Better Weight Loss
- Nov 19, 2025
- 2 min read
Recent research reports have provided important information on the outcomes of patients taking Semaglutide or Tirzepatide - and how you receive your medine and more importantly the amount of support that source provides can play a 2x to 5x difference in outcomes.
Real-World Discontinuation Rates Are Brutally High Without Support
Across dozens of large U.S. real-world studies in 2025, 40–65% of people stop GLP-1s (semaglutide or tirzepatide) within the first year when self-managing or using minimal-oversight telehealth/direct-to-consumer programs.
The #1 reason? Side effects (nausea, fatigue), cost, or simply losing motivation when appetite returns and old habits creep back.
In contrast, structured programs (especially ones with regular coaching, nutrition counseling, body-composition tracking, and group support) routinely show 20–40% better persistence and 2–5× higher odds of staying on the drug long enough to reach maintenance doses.
Weight-Loss Outcomes Are Dramatically Better When People Actually Stay on the Drug + Change Habits
Scenario (2025 real-world data) | Average 1-Year Weight Loss | % Achieving ≥15% Loss | Persistence Rate |
| 5–9% | 15–25% | 35–55% |
| 8–12% | 25–35% | 45–60% |
| 14–18% | 40–55% | 65–80% |
| 15–21% | 50–70% | 70–90% |
The best in-person/academic clinics measured in 2025 are now hitting numbers that match or beat the original phase-3 trials done by the makers of these medications — precisely because they keep people titrating up, manage side effects aggressively, and teach real behavioral skills (protein goals, proper hydration, resistance training, sleep, and stress management).
